Lincomycin microbiology
| Lincomycin |
|---|
| LINCOCIN®, LINCOMED®, LINCOMIX® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| How Supplied |
| Compatiblity |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Microbiology
Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (seeINDICATIONS AND USAGE).
Staphylococcus aureus (penicillinase- and non-penicillinase producing strains) Streptococcus pneumoniae
The following in vitro data are available; but their clinical significance is unknown.
Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of LINCOCIN in treating clinical infections due to these organisms have not been established in adequate and well controlled trials.
Aerobic gram-positive cocci:
Streptococcus pyogenes Viridans group streptococci
Aerobic gram-positive bacilli:
Corynebacterium diphtheriae
Anaerobic gram-positive non-sporeforming bacilli:
Propionibacterium acnes
Anaerobic gram-positive sporeforming bacilli:
Clostridium tetani Clostridium perfringens
This drug is not active against most strains of Enterococcus faecalis nor against Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae or other gram-negative organisms or yeasts.
Cross resistance has been demonstrated between clindamycin and lincomycin. Some cross resistance with erythromycin including a phenomenon known as dissociated cross resistance or macrolide effect has been reported.
Studies indicate that lincomycin does not share antigenicity with penicillin compounds.
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050317s172lbl.pdf